ArthNow Logo
ArthNow
•2 min read•
✦Reported by MoneyControl

Buy Indiqube Spaces; target of Rs 271: ICICI Securities

Buy Indiqube Spaces; target of Rs 271: ICICI Securities
Source: MoneyControl

Executive Brief • Key Highlights

Fast factual intelligence distilled for busy investors, executives, and answer bots:

  • ✓ICICI Securities issued a buy rating for Indiqube Spaces with a target price of Rs 271.
  • ✓The company delivered strong Q2FY27 results as mature centre occupancy rose to 91 percent.
  • ✓Revenue grew 12 percent, and management said growth momentum would sustain as new office space becomes operational later this year.

Story at a Glance

Category
Indian Markets
Reported By
MoneyControl
Reading Speed
2 Minute(s)
Market Focus
India Economy

ICICI Securities's research report on Indiqube Spaces Indiqube Spaces Ltd. (Indiqube) delivered a strong Q2FY27 result on the back of mature centre occupancy rising 100bps QoQ to 91%. Hence, Q2FY27 revenue was up 12% QoQ with IGAAP EBITDA (cash EBIT) up 39% QoQ to INR 1bn at an IGAAP EBITDA margin of 22% (up 430bps QoQ) owing to higher VAS margins of 20%. For the remainder of FY27, management is confident that growth momentum would sustain, with 1-1.5msf of new area becoming operational. We build in a 26% revenue CAGR and 32% IGAAP EBITDA CAGR over FY26-28E. We retain BUY with a revised TP of INR 271 (earlier INR 263) at 15x Sep'27E EV/EBITDA, as we raise our FY27-28E EBITDA by 2%, factoring in higher IGAAP EBITDA margin.

🔒
Premium Content

Unlock the Full Story with ArthNow Premium

To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.

✓ Full Unabridged Reports✓ Executive Audio Briefs✓ 100% Ad-Free Reading
Verified Publication Source

MoneyControl

Read the full, original unfiltered story directly on the publisher's portal.

Visit Original Article

This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.